Back to Browse Journals » International Journal of Nephrology and Renovascular Disease » Volume 1

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

Authors James B Wetmore, L Darryl Quarles

Published 13 November 2008 Volume 2008:1 Pages 5—17

DOI http://dx.doi.org/10.2147/IJNRD.S4368

Review by Single-blind

Peer reviewer comments 7

James B Wetmore1, L Darryl Quarles1,2

1Department of Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA; 2The Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA

Abstract: There is a growing understanding of the pathophysiology of secondary hyperparathyroidism (SHPT) and a recent emergence of new agents for SHPT treatment in patients with advanced kidney disease. At the same time, appreciation that mineral metabolic derangements promote vascular calcification and contribute to excess mortality, along with recognition of potentially important “non-classical” actions of vitamin D, have prompted the nephrology community to reexamine the use of various SHPT treatments, such as activated vitamin D sterols, phosphate binders, and calcimimetics. In this review, the evidence for treatment of SHPT with calcimimetics and vitamin D analogs is evaluated, with particular consideration given to recent clinical trials that have reported encouraging findings with cinacalcet use. Additionally, several controversies in the pathogenesis and treatment of SHPT are explored. The proposition that calcitriol deficiency is a true pathological state is challenged, the relative importance of the vitamin D receptor and the calcium sensing receptor in parathyroid gland function is summarized, and the potential relevance of non-classical actions of vitamin D for patients with advanced renal disease is examined. Taken collectively, the balance of evidence now supports a treatment paradigm in which calcimimetics are the most appropriate primary treatment for SHPT in the majority of end stage renal disease patients, but which nevertheless acknowledges an important role for modest doses of activated vitamin D sterols.

Keywords: secondary hyperparathyroidism, vitamin D, vitamin D receptor, calcium sensing receptor, calcimimetics, kidney disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Childhood asthma and anthropogenic CO2 emissions

Dosanjh A

Journal of Asthma and Allergy 2011, 4:103-105

Published Date: 10 October 2011

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

Stiffness of the large arteries in individuals with and without Down syndrome

Rodrigues AN, Coelho LC, Goncalves WLS, Gouvea SA, Vasconcellos MJR, Cunha RS, Abreu GR

Vascular Health and Risk Management 2011, 7:375-381

Published Date: 9 June 2011

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms

Joseph Tripodi, Ronald Hoffman, Vesna Najfeld, et al

Cancer Management and Research 2010, 2:219-223

Published Date: 17 September 2010

Insights into the classification of small GTPases

Dominik Heider, Sascha Hauke, Martin Pyka, et al

Advances and Applications in Bioinformatics and Chemistry 2010, 3:15-24

Published Date: 21 May 2010

Management of superficial basal cell carcinoma: focus on imiquimod

Beverly Raasch

Clinical, Cosmetic and Investigational Dermatology 2009, 2:65-75

Published Date: 11 June 2009

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate

Veerle P Persy, Geert J Behets, Marc E De Broe, Patrick C D’Haese

International Journal of Nephrology and Renovascular Disease 2009, 2:1-8

Published Date: 1 April 2009

Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care

Carl Llor, Silvia Hernández, Anna Ribas, Carmen Álvarez, Josep Maria Cots, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:45-53

Published Date: 15 October 2008